Canterbury DHB

Context

Acquired Platelet Function Defects

In This Section

Uraemia

Hepatic Cirrhosis

Myeloproliferative Disorders

Uraemia

Desmopressin normalises the uraemic bleeding time prolongation in approximately 75% of patients at one hour after beginning the infusion. The effect lasts four/six hours. This shortening of bleeding time to below 10 minutes is still present in a majority of patients, even after four hours. There are no controlled trials that show that desmopressin stops spontaneous bleeding or prevents excessive blood loss after surgery.

Hepatic Cirrhosis

Desmopressin may shorten a prolonged bleeding time in patients with cirrhosis. Consider using in those patients undergoing invasive procedures. Cases in which plasma infusions fail to normalise coagulation may respond to desmopressin. Check bleeding time response. There are no controlled trials to establish the efficacy of desmopressin in arresting blood loss in cirrhotic patients with a prolongation of the bleeding time.

Myeloproliferative Disorders

The platelet defect in patients with myeloproliferative disorders is variably responsive to desmopressin infusion.

About this Canterbury DHB document (5283):

Document Owner:

Mark Smith (see Who's Who)

Issue Date:

August 2016

Next Review:

August 2019

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5283